Patents by Inventor Eric Ariazi

Eric Ariazi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20260085351
    Abstract: Methods and systems provided herein address current limitations of bisulfite-based methylation sequencing by improving the quality and accuracy of nucleic acid methylation sequencing and uses thereof for detection of disease. Methods that include minimally-destructive conversion methods for methylation sequencing as well as specialized UMI adapters provide for improved quality of sequencing libraries and sequencing information. Greater accuracy and more complete methylation-state information permits higher quality feature generation for use in machine learning models and classifier generation.
    Type: Application
    Filed: October 1, 2025
    Publication date: March 26, 2026
    Inventors: Eric ARIAZI, David WEINBERG, Greg HOGAN, John ST. JOHN, Michael PEARSON
  • Patent number: 12503728
    Abstract: Methods and systems provided herein address current limitations of bisulfite-based methylation sequencing by improving the quality and accuracy of nucleic acid methylation sequencing and uses thereof for detection of disease. Methods that include minimally-destructive conversion methods for methylation sequencing as well as specialized UMI adapters provide for improved quality of sequencing libraries and sequencing information. Greater accuracy and more complete methylation-state information permits higher quality feature generation for use in machine learning models and classifier generation.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: December 23, 2025
    Assignee: Freenome Holdings, Inc.
    Inventors: Eric Ariazi, David Weinberg, Greg Hogan, John St. John, Michael Pearson
  • Patent number: 12454724
    Abstract: Methods and systems provided herein address current limitations of bisulfite-based methylation sequencing by improving the quality and accuracy of nucleic acid methylation sequencing and uses thereof for detection of disease. Methods that include minimally-destructive conversion methods for methylation sequencing as well as specialized UMI adapters provide for improved quality of sequencing libraries and sequencing information. Greater accuracy and more complete methylation-state information permits higher quality feature generation for use in machine learning models and classifier generation.
    Type: Grant
    Filed: February 1, 2023
    Date of Patent: October 28, 2025
    Assignee: Freenome Holdings, Inc.
    Inventors: Eric Ariazi, David Weinberg, Greg Hogan, John St. John, Michael Pearson
  • Publication number: 20240240257
    Abstract: The present disclosure provides oligonucleotide adapter compositions, methods, and systems for improved resolution of 5hmC sequencing useful for improving nucleic acid sequencing library quality and nucleic acid methylation profiling. Also provided are methods of applying the improved oligonucleotide adapters and sequencing methods for machine learning classifier generation, and detecting cell proliferative disorders such as cancer. Methods of applying targeted nucleic acid enrichment with methods of applying the improved oligonucleotide adapters and sequencing methods for improving nucleic acid sequencing library quality and nucleic acid methylation profiling are also provided.
    Type: Application
    Filed: January 19, 2024
    Publication date: July 18, 2024
    Inventors: Eric ARIAZI, Paula ESQUETINI, Aneesha TEWARI, David WEINBERG
  • Publication number: 20240202603
    Abstract: Systems and methods that analyze blood-based cancer diagnostic tests using multiple classes of molecules are described. The system uses machine learning (ML) to analyze multiple analytes, for example cell-free DNA, cell-free microRNA, and circulating proteins, from a biological sample. The system can use multiple assays, e.g., whole-genome sequencing, whole-genome bisulfite sequencing or EM-seq, small-RNA sequencing, and quantitative immunoassay. This can increase the sensitivity and specificity of diagnostics by exploiting independent information between signals. During operation, the system receives a biological sample, and separates a plurality of molecule classes from the sample. For a plurality of assays, the system identifies feature sets to input to a machine learning model. The system performs an assay on each molecule class and forms a feature vector from the measured values.
    Type: Application
    Filed: November 22, 2023
    Publication date: June 20, 2024
    Inventors: Adam Drake, Daniel Delubac, Katherine Niehaus, Eric Ariazi, Imran Haque, Tzu-Yu Liu, Nathan Wan, Ajay Kannan, Brandon White
  • Patent number: 11847532
    Abstract: Systems and methods that analyze blood-based cancer diagnostic tests using multiple classes of molecules are described. The system uses machine learning (ML) to analyze multiple analytes, for example cell-free DNA, cell-free microRNA, and circulating proteins, from a biological sample. The system can use multiple assays, e.g., whole-genome sequencing, whole-genome bisulfite sequencing or EM-seq, small-RNA sequencing, and quantitative immunoassay. This can increase the sensitivity and specificity of diagnostics by exploiting independent information between signals. During operation, the system receives a biological sample, and separates a plurality of molecule classes from the sample. For a plurality of assays, the system identifies feature sets to input to a machine learning model. The system performs an assay on each molecule class and forms a feature vector from the measured values.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: December 19, 2023
    Assignee: Freenome Holdings, Inc.
    Inventors: Adam Drake, Daniel Delubac, Katherine Niehaus, Eric Ariazi, Imran Haque, Tzu-Yu Liu, Nathan Wan, Ajay Kannan, Brandon White
  • Publication number: 20230323446
    Abstract: Methods and systems provided herein address current limitations of bisulfite-based methylation sequencing by improving the quality and accuracy of nucleic acid methylation sequencing and uses thereof for detection of disease. Methods that include minimally-destructive conversion methods for methylation sequencing as well as specialized UMI adapters provide for improved quality of sequencing libraries and sequencing information. Greater accuracy and more complete methylation-state information permits higher quality feature generation for use in machine learning models and classifier generation.
    Type: Application
    Filed: February 1, 2023
    Publication date: October 12, 2023
    Inventors: Eric ARIAZI, David WEINBERG, Greg HOGAN, John ST. JOHN, Michael PEARSON
  • Patent number: 11681953
    Abstract: Systems and methods that analyze blood-based cancer diagnostic tests using multiple classes of molecules are described. The system uses machine learning (ML) to analyze multiple analytes, for example cell-free DNA, cell-free microRNA, and circulating proteins, from a biological sample. The system can use multiple assays, e.g., whole-genome sequencing, whole-genome bisulfite sequencing or EM-seq, small-RNA sequencing, and quantitative immunoassay. This can increase the sensitivity and specificity of diagnostics by exploiting independent information between signals. During operation, the system receives a biological sample, and separates a plurality of molecule classes from the sample. For a plurality of assays, the system identifies feature sets to input to a machine learning model. The system performs an assay on each molecule class and forms a feature vector from the measured values.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: June 20, 2023
    Assignee: Freenome Holdings, Inc.
    Inventors: Adam Drake, Daniel Delubac, Katherine Niehaus, Eric Ariazi, Imran Haque, Tzu-Yu Liu, Nathan Wan, Ajay Kannan, Brandon White
  • Publication number: 20210230684
    Abstract: Methods and systems provided herein address current limitations of bisulfate-based methylation sequencing by improving the quality and accuracy of nucleic acid methylation sequencing and uses thereof for detection of disease. Methods that include minimally-destructive conversion methods for methylation sequencing as well as specialized UMI adapters provide for improved quality of sequencing libraries and sequencing information. Greater accuracy and more complete methylation-state information permits higher quality feature generation for use in machine learning models and classifier generation.
    Type: Application
    Filed: February 11, 2021
    Publication date: July 29, 2021
    Inventors: Eric ARIAZI, David WEINBERG, Greg HOGAN, John ST. JOHN, Michael PEARSON
  • Publication number: 20210210205
    Abstract: Systems and methods that analyze blood-based cancer diagnostic tests using multiple classes of molecules are described. The system uses machine learning (ML) to analyze multiple analytes, for example cell-free DNA, cell-free microRNA, and circulating proteins, from a biological sample. The system can use multiple assays, e.g., whole-genome sequencing, whole-genome bisulfite sequencing or EM-seq, small-RNA sequencing, and quantitative immunoassay. This can increase the sensitivity and specificity of diagnostics by exploiting independent information between signals. During operation, the system receives a biological sample, and separates a plurality of molecule classes from the sample. For a plurality of assays, the system identifies feature sets to input to a machine learning model. The system performs an assay on each molecule class and forms a feature vector from the measured values.
    Type: Application
    Filed: February 11, 2021
    Publication date: July 8, 2021
    Inventors: Adam Drake, Daniel Delubac, Katherine Niehaus, Eric Ariazi, Imran Haque, Tzu-Yu Liu, Nathan Wan, Ajay Kannan, Brandon White
  • Publication number: 20210174958
    Abstract: Systems and methods that analyze blood-based cancer diagnostic tests using multiple classes of molecules are described. The system uses machine learning (ML) to analyze multiple analytes, for example cell-free DNA, cell-free microRNA, and circulating proteins, from a biological sample. The system can use multiple assays, e.g., whole-genome sequencing, whole-genome bisulfite sequencing or EM-seq, small-RNA sequencing, and quantitative immunoassay. This can increase the sensitivity and specificity of diagnostics by exploiting independent information between signals. During operation, the system receives a biological sample, and separates a plurality of molecule classes from the sample. For a plurality of assays, the system identifies feature sets to input to a machine learning model. The system performs an assay on each molecule class and forms a feature vector from the measured values.
    Type: Application
    Filed: April 15, 2019
    Publication date: June 10, 2021
    Inventors: Adam Drake, Daniel Delubac, Katherine Niehaus, Eric Ariazi, Imran Haque, Tzu-Yu Liu, Nathan Wan, Ajay Kannan, Brandon White
  • Publication number: 20050118658
    Abstract: The inventors discovered that the ErbB2 signal transduction pathway can activate ERR? by inducing its phosphorylation. Based on this discovery, the present invention provides methods for determining whether a breast cancer patient is likely to respond to hormonal-blockade therapy or ErbB2-based therapy, methods for determining prognosis of breast cancer patients, methods for treating breast cancer, and methods for identifying agents that can modulate ERR? phosphorylation.
    Type: Application
    Filed: September 16, 2004
    Publication date: June 2, 2005
    Inventors: Janet Mertz, Eric Ariazi, Richard Kraus